Get the latest tech news
Path to precision: Targeted cancer drugs go from table to trials to bedside
What started in a scientist's dining room is now in tissue-agnostic combo trials.
Later that same year, she saw another translocation, this time in patients with a different type of blood cancer, called chronic myelogenous leukemia (CML). In 1977, Rowley and two of her colleagues at the University of Chicago identified another chromosomal translocation— 15;17 —that causes a rare blood cancer called acute promyelocytic leukemia. For instance, the TKIs lapatinib, neratinib, tucatinib, and pyrotinib target human epidermal growth factor receptor 2 (HER2), which runs amok in some breast and gastric cancers.
Or read this on r/technology
